Skip to main content
SpringerLink
Log in

Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations

  • Original
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

The effects of glimepiride, the newest sulphonylureic compound, on pancreatic insulin and glucagon secretion were studied using the classical, isolated, perfused rat pancreas model. The influence of four different environmental glucose conditions (during a glycaemic stimulus with glucose increasing from 5 to 8.33 mM and at stable 0, 5 and 2.22 mM glucose levels) on the effects of glimepiride was also assessed. At a pharmacological concentration glimepiride strongly stimulated beta-cell activity, producing a characteristic biphasic insulin release with a sharp first-phase secretory peak, followed by a prolonged and sustained second phase. Environmental glucose concentrations markedly influenced the extent, but not the pattern of glimepiride-induced insulin secretion, as hormone release dropped significantly when the glucose level was reduced. Glimepiride failed to influence alpha-cell activity at any of the environmental glycaemic levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gerich JE, Oral hypoglycemic agents. N Engl J Med 321: 1231–1245, 1989

    Google Scholar 

  2. Groop LC, Sulfonylureas in NIDDM. Diabetes Care 15: 737–754, 1992

    Google Scholar 

  3. Geisen K, Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung 38:1120–1130, 1988

    Google Scholar 

  4. Lebrun P, Malaisse WJ, Cationic and secretory effects of glimepiride and glibenclamide in perfused rat islets. Pharmacol Toxicol 70:357–360, 1992.

    Google Scholar 

  5. Leclercq-Meyer V, Akkan AG, Marchand J, Malaisse WJ, Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas. Biochem Pharmacol 42:1634–1637, 1991

    Google Scholar 

  6. Marynissen G, Smets G, Klöppel G, Gerlache L, Malaisse WJ, Internalization of glimepiride and glibenclamide in pancreatic B-cell. Acta Diabetol 29:113–114, 1992

    Google Scholar 

  7. Lehr KH, Damm P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. J Chromatogr Biomed Appl 526:497–505, 1990

    Google Scholar 

  8. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W, Determination of absolute bioavailability of glimepiride (HOE490), a new sulphonylurea. Int J Clin Ther Toxicol 30: 481–482, 1992

    Google Scholar 

  9. Ladik T, Lotz N, Rupp P, Mehnert H, Efficacy of the new sulfonylurea glimepiride in the treatment of type 2 diabetes. Diab Res Clin Pract 5 [Suppl 1]: 257, 1988

    Google Scholar 

  10. Rosenkranz S, Malerczyk V, Lehr KH, Profozic V, Mrzljak V, Skrabalo Z, Pharmacokinetics of glimepiride in kidney disease. Clin Parmacol Ther 49 [Suppl 2]: 170, 1991

    Google Scholar 

  11. Wernicke-Panten K, Haupt E, Pfeiffer C, Mayer A, Drager KE, Early onset of pharmacodynamic effects of glimepiride in type II diabetic patients. Diabetologica 37 [Suppl 1]: A163, 1994

  12. Tsumura K-I, Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diab Res Clin Pract 28 [Suppl]:S145-S149, 1995

    Google Scholar 

  13. Draeger E, Lomp HJ, Rosskamp R, Multicentre clinical trial to study the effects of glimepiride during long term treatment of type II diabetic patients. 15th Int Diabetes Federation Congress, Kobe (Abstract 10A5 PP 1051), 1994

  14. Draeger E, Clinical profile of glimepiride. Diab Res Clin Pract 28 [Suppl]:S139-S146, 1995

    Google Scholar 

  15. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD, Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. II Photoaffinity labeling of 64 kDa protein by [3H]glimepiride. Biochem Biophys Acta 1191:278–290, 1994

    Google Scholar 

  16. Kramer W, Oekonomopulos R, Pünter J, Summ HD, Direct photoaffinity labeling of the putative sulfonylurea receptor in rat β-cell tumor membranes by [3H]glibenclamide. FEBS Lett 229:355–359, 1988

    Google Scholar 

  17. Kramer W, Müler G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD, The molecular interaction of sulfonylureas with the ATP-sensitive K+-channels. Diab Res Clin Prac 28 [Suppl]:S67-S80, 1995

    Google Scholar 

  18. Müller G, Hartz D, Pünter J, Oekonomopulos R, Kramer W, Differential interactions of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochem Biophys Acta 1191:267–277, 1994

    Google Scholar 

  19. Müller G, Satoh Y, Geisen K, Extrapancreatic effects of sulfonylureas — a comparison between glimepiride and conventional sulfonylureas. Diab Res Clin Pract 28 [Suppl]:S115-S137, 1995

    Google Scholar 

  20. Herz M, Effects of physical exercise on metabolic control in NIDDM patients treated with glimepiride and glibenclamide. 15th Int Diabetes Federation Congress, Kobe (Abstract 10A5 PP 0987), 1994

  21. Samols E, Tyler JM, Mialhe P, Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet 25:174–176, 1979

    Google Scholar 

  22. Tsalikian E, Dunphy TW, Bohannon NV, Lorenzi M, Gerich JE, Forsham PH, Kane JP, Karam JH, The effect of chronic oral antidiabetic therapy on insulin and glucagon response to meal. Diabetes 26:314–321, 1977

    Google Scholar 

  23. Fallucca F, Iavicoli M, Menzinger G, Mirabella C, Andreani D, Glucagon and growth hormone secretion in insulin-treated diabetics: effects of added sulfonylureas. Metabolism 27:5–11, 1978

    Google Scholar 

  24. Pfeifer MA, Beard JC, Halter JB, Judzewitsch R, Best JD, Porte D Jr, Suppression of glucagon secretion during a tolbutamide infusion in normal and noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 56:586–591, 1983

    Google Scholar 

  25. Ostenson CG, Nylén A, Grill V, Efendic S, Sulfonylurea-induced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct, non-paracrine effect. Diabetologia 29: 861–867, 1996

    Google Scholar 

  26. Pek S, Fajans SS, Floyd JC, Knopf RF, Conn JW, Arbor A, Failure of sulfonylureas to suppress plasma glucagon in man. Diabetes 21:216–223, 1972

    Google Scholar 

  27. Marco J, Valverde I, Unaltered glucagon secretion after seven days of sulphonylurea administration in normal subjects. Diabetologica 9:317–319, 1973

    Google Scholar 

  28. Gregorio F, Ambrosi F, Cristallini S, Pedetti M, Filipponi P, Santeusanio F, Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diab Res Clin Part 18:197–206, 1992

    Google Scholar 

  29. Gregorio F, Ambrosi F, Filipponi P, Cristallini S, Santeusanio F, Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas. J Diabetic Complications 8:204–212, 1994

    Google Scholar 

  30. Weir CG, Leahy JL, Barres E, Braunstein LP, Characteristics of insulin and glucagon release from the perfused pancreas, intact isolated islets and dispersed islet cells. Hormone Res 24:62–72, 1986

    Google Scholar 

  31. Sussman KE, Vaughan GD, Timer RF, An in vitro method for studying insulin secretion in the perfused isolated rat pancreas. Metabolism 15:466–476, 1966

    Google Scholar 

  32. Scharff R, Wool IG, Concentrations of amino acids in rat muscle and plasma. Nature 202:603–604, 1964

    Google Scholar 

  33. Unger RH, Insulin-glucagon relationships in the defense against hypoglycemia. Diabetes 32:575–583, 1983

    Google Scholar 

  34. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH, Insulin within islets in a physiologic glucagon release inhibitor. J Clin Invest 74:2296–2299, 1984

    Google Scholar 

  35. Filipponi P, Gregorio F, Cristallini S, Ferrandina C, Nicoletti I, Santeusanio F, Selective impairment of pancreatic A-cell suppression by glucose during acute alloxan-induced insulinopenia: in vitro study on isolated perfused rat pancreas. Endocrinology 119:408–415, 1986

    Google Scholar 

  36. Bolli G, De Feo P, Periello G, DeCosmo S, Compagnucci P, Santeusanio F Brunetti P, Unger RH, Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man: role of the beta-cell and arterial hyperinsulinemia. J Clin Invest 73: 917–922, 1984

    Google Scholar 

  37. DeFronzo RA, The triumvirate β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667–687, 1988

    Google Scholar 

  38. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schaklin C, Groop L, Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 321:337–343, 1989

    Google Scholar 

  39. Leahy JL, Bonner-Weir S, Weir GC, β-cell dysfunction induced by chronic hyperglycemia. Diabetes Care 15: 442–445, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Endocrine and Metabolic Science, University of Perugia, Via del Giochetto, I-06100, Perugia, Italy

    F. Gregorio & F. Santeusanio

  2. Metabolic Unit, Department of Internal Medicine, Pathology and Pharmacology, University of Perugia, Perugia, Italy

    F. Ambrosi, S. Cristallini & P. Filipponi

Authors
  1. F. Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ambrosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Cristallini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Filipponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Santeusanio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gregorio, F., Ambrosi, F., Cristallini, S. et al. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetol 33, 25–29 (1996). https://doi.org/10.1007/BF00571936

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00571936

Key words

Search

Navigation